Podcasts about biopsies

Neurologic complications of hematologic disorders are frequently encountered in clinical practice and can involve both the central and peripheral nervous systems. Early recognition and appropriate management in collaboration with a hematologist are essential to reduce morbidity and mortality. In this episode, Kait Nevel, MD, speaks with Lauren Patrick, MD, and Mark Terrelonge, MD, MPH, authors of the article "Neurologic Complications of Hematologic Disorders" in the Continuum® February 2026 Neurology of Systemic Disease issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Patrick is an assistant professor of neurology at the University of California, San Francisco, in San Francisco, California. Dr. Terrelonge is an associate professor of neurology at the University of California, San Francisco, in San Francisco, California. Additional Resources Read the article: Neurologic Complications of Hematologic Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Nevel: Thick blood, thin blood. These are terms often used by patients and caregivers to describe some of the hematologic disorders that can lead to neurological diseases such as stroke. So, when should we consider a hematologic disorder as a potential cause for neurological conditions, such as stroke or neuropathy. Today I have the opportunity to interview Drs Lauren Patrick and Mark Terrelonge to learn more about neurologic complications of hematologic disorders in their recent article in Continuum. Dr Jones: This is Dr Lyell Jones, editor-in-chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Drs Lauren Patrick and Mark Terrelonge about their article on neurologic complications of hematologic disorders. This article appears in the February 2026 Continuum issue on neurology of systemic disease. Welcome to the podcast, and please introduce yourself to the audience. Dr Patrick: Thank you for having us. We're both thrilled to be here. I'm Lauren Patrick, a vascular neurologist and assistant professor at the University of California, San Francisco, and program director for the Vascular Neurology Fellowship here. Dr Terrelonge: And I'm Mark Terrelonge, I'm an associate professor of neurology and neuromuscular medicine here at UCSF and one of the associate program directors for the adult neurology residency. Nice to meet you. Dr Nevel: Nice to meet you both. Really looking forward to getting into your article and learning more. So, to kind of kick us off, I always like to ask what do you think is the most important takeaway from your article for the practicing neurologist? And maybe since there are two of you and I suspect you covered slightly different aspects of this article, maybe you could give us two most important takeaways. Dr Patrick: Sure. I think the biggest takeaway is to keep hematologic disorders on the differential when evaluating patients with neurologic symptoms. Conditions like sickle cell disease, myeloproliferative neoplasms, or plasma cell dyscrasias and paraproteinemia can cause strokes or peripheral neuropathies, and many have specific and targetable treatments. The early recognition and collaboration with our hematology colleagues can truly change patient outcomes, whether that's by initiating cytoreductive therapy, managing thrombocytopenia, or optimizing antithrombotic therapy. Dr Nevel: Great. So, this is a really big and diverse topic. As always, I'm going to urge our listeners to read the article because there is a lot of really good stuff in your article that we just don't have time to get into during this interview today. But you cover a lot of different hematological disorders and how they can cause neurological complications. One of the major neurological complications of hematological disorders is cerebral vascular events. So, I'm hoping, Warren, that you can walk us through a little bit. When should we consider workup of potential hematologic disorder as a cause when we see a patient with ischemic stroke, because certainly not all patients with ischemic stroke should be getting a broad hematological disorder work up. So how can we kind of identify early on that there might be something else at play? Dr Patrick: Absolutely, great question. So, in many cases, the underlying hematologic disorder is already known, such as sickle cell disease or polycythemia vera. But sometimes stroke is the initial presentation or manifestation of the disease. So red flags can include young age, recurrent cryptogenic strokes or thrombosis, and unusual locations like the cerebral venous system. Laboratory clues such as unexplained erythrocytosis, thrombocytosis, thrombocytopenia, or hemolytic anemia should raise suspicion for an occult hematologic disorder. In the setting of acute illness, immune-mediated or heparin-induced thrombocytopenia or thrombotic microangiopathies should be suspected in patients that have hemorrhagic and or thrombotic complications, particularly when relevant lab disturbances are present. Acquired thrombophilia such as anti-phospholipid antibody syndrome should be considered in young patients with autoimmune disease, prior venous or arterial thrombotic complications, or pregnancy morbidity. Now, these are rare causes overall, but they're important to catch because the management can differ dramatically from our typical stroke care. Dr Nevel: Great. And what are some of the most common inherited or acquired thrombophilias and when should we be sending these labs? Dr Patrick: The hematologic causes really account for small minority of arterial strokes approximately one to two percent, but among those, sickle cell disease, anti-phospholipid antibody syndrome and the myeloproliferative neoplasms are the most common. Timing of testing is key. So, the genetic thrombophilia panels can be drawn at presentation, but lab values such as protein C, protein S, and antithrombin levels may be falsely low during acute thrombosis, so they're often repeated weeks later. Similarly, for anti-phospholipid antibody testing that should be done at presentation and when positive, confirmed at twelve weeks, since transient positivity can occur with affections or acute events. So, in patients that are already anticoagulated for anti-phospholipid antibody syndrome, testing becomes particularly tricky, especially with lupus anticoagulant assays. Some results need to be interpreted carefully or repeated when feasible. The main message is to collaborate early with our hematology colleagues to guide the timing and interpretation of these studies. Dr Nevel: Yeah, wonderful. Thank you. I'll ask some similar questions about neuropathy. So when should we consider an underlying hematologic disorder as being the cause for someone's neuropathy? Dr Terrelonge: So, luckily for a neurologist, then serum protein electrophoresis or an SPEP is already a part of the first pass evaluation for even the most common neuropathies we see, technically already considered every time we do an evaluation. However, we do know that most neuropathies progress very slowly and don't really lead to significant limitations in patient activities of daily living. And for those, the initial workup step, you may not need to do any additional search for any hematologic diseases after that first step. Within patients who start to have more unusual features with their neuropathy, including a rapid progression, early proximal weakness, significant and extremely painful neuropathies, significant ataxia, or new tremor or anything that's kind of outside of the garden variety neuropathy, then you should start to think about a hematologic cause. Additionally, if a patient already has a known hematologic malignancy or process before their neuropathy, there should be some form of assessment to see through exam or electrodiagnostically if the two are correlated. I do have to add one caveat, though, and that's just because someone has a hematologic malignancy or a paraprotein seen in their blood, their neuropathy and the neurologic syndrome don't necessarily have to be causally related. So, we have to do some additional testing to determine if the patient's presentation of the paraprotein are actually linked. Dr Nevel: Can you walk us through a little bit how we determine if they're associated or just coincidental? Dr Terrelonge: Yeah. So, for some of the proteins, there's a specific phenotype that will come with the specific protein. For example, an anti MAG proteinopathies or MAG standing for a myelin associated glycoprotein, it usually leads to a distal sensor and motor polyneuropathy where the most distal portions of nerves are affected. So, in that case, people might notice that they have numbness and weakness in their toes and their fingers, and it doesn't follow that typical length dependent pattern. So, in that case, if you have the anti mag neuropathy and the electrodiagnostic signature of an anti mag neuropathy along with the symptoms, you're more likely to think that the two are related then if not. Dr Nevel: Great. Thank you. And I was hoping you could speak a little bit more about amyloidosis just because I think that that's one that can be really tricky to diagnose. And I see patients, you know, have sometimes more drawn out evaluations or see multiple providers before a diagnosis is reached. So, can you speak a little bit more to how we diagnose amyloidosis in relationship to neuropathy or other neurological conditions and when we should push for more invasive testing like a nerve biopsy? Dr Terrelonge: So, amyloidosis certainly is a tricky diagnosis. I've been tricked by it and I think most of my neuromuscular colleagues have probably been tricked by it at least once. It's a hard diagnosis to make is it usually requires a pretty high index of suspicion, and also requires a tissue diagnosis to cinch. There're some patients who will come in with a prior history of amyloidosis and they're a little bit easier to figure out if the neuropathy is related. Maybe it's started in their heart or their kidney first and then you can just see if the type of amyloid they have usually deposits in nerve, and that may be enough. But if there's any diagnostic uncertainty, you could go forward with tissue biopsy. But it's patients in which the neuropathy is the first symptom that amyloidosis can be especially tricky to diagnose. It's a primarily light chain disease. So, if you do only an SPEP as a part of your initial neuropathy evaluation, you could miss it. But usually, the patients will have either a severely painful neuropathy, early autonomic dysfunction, or really prominent bilateral carpal tunnel syndrome. So, if they have any of those, usually we'll add in an amyloid workup as a part of that of the rest of the workup, which would include both light chain evaluations to see if there's any increase in Lambda or Kappa light chains and then also biopsy. Biopsy can be of the skin or fat pad first, which have reasonable sensitivity for picking up disease, but they're not necessarily a hundred percent. So if the suspicion remains high in those cases, a nerve biopsy should be considered. And the reason why this is important is that the chemotherapeutic agents that we have now can actually help arrest a lot of these diseases and stop further organ involvement. So, if you think about it, it is important to keep pushing and looking until you find it. Dr Nevel: Thank you so much for that. And a follow up question to that, once patients are started on appropriate therapy, the diagnosis is made, chemotherapy is started, what's the typical clinical course that you see in terms of their neuropathy? Do you ever see improvement or is it arrest of worsening? Dr Terrelonge: Usually for amyloid, there is an arrest of disease, but in some patients, they could have some improvement, not necessarily a dramatic improvement, but some patients could see some reversal of symptoms. That may not necessarily be because nerves injured nerves are regrowing, but because of reorganization of nerves to muscle, they could have some strength increases or at least less pain. Dr Nevel: Yeah, thank you. So, when should we involve a hematologist in aiding in the evaluation of patients we suspect may have an underlying hematological disorder? You guys really outlined very nicely in your article some of the laboratory workup or other workup like you just talked about with amyloidosis. But at what point in that workup should we reach out to our hematology colleagues? Dr Patrick: I would say almost always. So, these disorders are inherently multi-system and benefit from early co-management. In acute sickle cell stroke, for example, hematology helps direct emergent exchange transfusion. For myeloproliferative disorders they guide cyto reduction and long term antithrombotic strategy. And for antibody mediated or plasma cell disorders, hematology determines disease specific therapies. So, neurology may help with identifying the presentation, but the definitive management is almost always shared with our hematology colleagues. Dr Nevel: And as you both have mentioned that a lot of times in these cases, their hematologic disorder may be already known before they present with their neurological symptoms. So, I imagine obviously in those cases that a hematologist hopefully is already heavily involved in their care. What do you think is the most difficult aspect of identifying and diagnosing patients with neurologic illness as having an underlying hematological disorder? Dr Patrick: The hardest part is maintaining a high index of suspicion, especially since hematologic causes account for a very small minority of arterial strokes. Most strokes are from traditional vascular risk factors like you mentioned, or cardio embolism, so it's easy to stop diagnostic evaluation after standard studies have been performed. An example of a challenging case is a patient that's young, they've had recurrent cryptogenic stroke, and they could have antiphospholipid antibody syndrome, but it can be easy to miss if their antibody titers are borderline or if they're already anticoagulated, which would complicate retesting. So, it's about balancing the urge to over-test with recognizing the few cases where identifying A hematologic cause truly changes that management. Dr Terrelonge: And then on the neuropathy side, probably the hardest part is deciding what's causal and what's coincidence. Monoclonal gammopathy of unknown significance, or MGUS, is really common in older adults, so not every M-spike on an SPEP explains a neuropathy. And even sometimes there's times when the neurologic picture will develop a little bit faster than the hematologic one. So, it's hard to put the two together. Dr Nevel: Yeah. What's the most rewarding aspect of taking care of patients with complications from their hematologic disorders? Dr Patrick: It's deeply rewarding when a targeted diagnosis leads to a tangible improvement in that patient's care. For example, identifying A cryptogenic stroke is being due to myeloproliferative neoplasm or an inherited thrombophilia allows us to move from empiric treatment to possible disease specific strategy. It's really gratifying to give patients that clarity, to give them a diagnosis and in some cases prevent future events. Dr Terrelonge: Agreed. And even on the neuropathy side, almost all of the neuropathies that are hematologically related are treatable. So, it's so satisfying whenever you have a patient with say an anti-MAG neuropathy or Waldenström can start the patient on therapy, and you can see someone who's been having a progressive decline to stability and in those cases sometimes even significant recovery. Dr Nevel: Yeah, absolutely. Very rewarding when you can identify the problem and make it better. That's what it's all about. So, what are the future areas of research in this area? What do we still need to learn? Dr Patrick: There's still a lot to learn. I think we need better data on the safety of acute reperfusion therapy and antithrombotic agents, particularly in patients that are at dual risk for bleeding and thrombosis. Other examples, secondary prevention strategies and anti-phospholipid antibody syndrome. What's the best target INR? Do you add aspirin to warfarin or not? All of that is often left up to expert opinion. What's the best management for adults with sickle cell stroke? There are many open questions there. A lot of the protocols that we have in place for sickle cell patients that are adults as derived from pediatric literature and there's vast potential in terms of disease modifying therapies, especially in the fields of sickle cell disease and amyloidosis. And we'll need to reassess how those treatments may change neurologic outcomes. Dr Terrelonge: I think on the neuropathy side that having some form of new biomarkers to help us clearly know of the neuropathy and that hematologic illness are associated would be very helpful. On the treatment side, a lot of this is really being driven by the hematology space, but new therapies that treat hematologic plasma cell disorders, including some of the new BTK inhibitor, may be incorporated relatively soon into the algorithm for how we treat many of our patients. I'm excited to see what's to come from this. Dr Nevel: Wonderful. Thank you so much for sharing your knowledge with us today. I know I've certainly learned a lot by reading your article and through our discussion today. Highly encourage our listeners to read your wonderful article, which is a very thorough review of hematologic disorders and neurological complications. Again, today I've been interviewing Dr Lauren Patrick and Dr Mark Terrelonge on their article Neurologic Complications of Hematologic Disorders, which appears in the February 2026 Continuum issue on Neurology of Systemic Disease. Please be sure to check out Continuum Audio episodes from this and other issues. And as always, thank you so much to our listeners for joining today, and thank you so much to Lauren and Mark. Dr Terrelonge: Yeah, thank you so much for having us. Dr Patrick: Thank you so much for having us and for highlighting this topic. We hope the issue encourages clinicians to think broadly about hematologic causes of neurologic disease and to continue collaborating closely with our hematology colleagues. It's a complex but very fascinating intersection for both of our fields. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

February 20, 2026 In this episode, Scott, Mark, and Dr. Ray Painter break down the financial realities of the new prostate biopsy CPT codes and what they mean for urology practices. Moving beyond coding mechanics, the discussion focuses on the economic differences between transrectal and transperineal approaches, MRI fusion versus ultrasound guidance, targeted lesion add-on payments, and the site-of-service differential between office and facility settings. They explore how practice expense values, capital equipment costs, disposable supplies, physician time, and block scheduling all factor into the decision to bring advanced biopsy techniques in-house. The episode emphasizes balancing clinical judgment with financial sustainability—helping practices evaluate whether expanding in-office prostate biopsy services makes sense now and in the future. PRS Coding and Reimbursement HubAccess the HubFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Are mammograms truly protecting women — or is it time to rethink how we approach breast health? In this powerful and deeply nuanced conversation, Dr. Anna Cabeca sits down with former fellowship-trained breast surgeon turned integrative oncologist Dr. Jenn Simmons to unpack one of the most important questions in women's health today: Are mammograms safe — and are they enough? Together, they explore how conventional breast cancer screening became the standard, what the research actually says about radiation exposure and screening frequency, and why early detection is not the same as prevention. Dr. Simmons shares her personal turning point — from 17 years at the forefront of breast oncology to leaving conventional medicine and founding Real Health MD after her own health crisis. What she discovered changed everything: inflammation, toxicity, hormone disruption, and metabolic dysfunction matter far more than women are being told. This episode goes beyond mammograms. It dives into: • Radiation risks and over-screening • Alternative imaging options including thermography, ultrasound, and emerging technologies • Hormones and breast cancer — clearing the misinformation • Why anti-estrogen messaging can be harmful and incomplete • Bioidentical progesterone and protective mechanisms • Birth control pills and breast development risk • The power of metabolic health, fasting windows, detoxification, and terrain theory Most importantly, this conversation restores agency. You are not powerless when it comes to breast health. Knowledge is evolving. Screening is evolving. Hormone science is evolving. And you deserve the full picture. –––––––––––––––––– KEY TIMESTAMPS 00:00 Reimagining breast health and questioning the narrative 01:23 Introducing Dr. Jenn Simmons and her paradigm shift 09:47 From breast surgeon to integrative oncologist: her turning point 12:28 Functional medicine approach: "What caused the cancer?" 27:19 Mammography myths and reviewing the research 33:01 Radiation exposure: known carcinogen discussion 35:31 Biopsy concerns and imaging alternatives 42:07 Medical board pressures and guideline rigidity 53:04 "Anti-estrogen talk is misogynistic" 01:04:10 Birth control pills, teens, and breast cancer risk –––––––––––––––––– MEMORABLE QUOTES Dr. Jenn Simmons: "Radiation is a known carcinogen." "Any anti-estrogen talk is misogynistic." Dr. Anna Cabeca: "What caused your cancer to begin with?" "It takes more than hormones to fix our hormones." "There's always one next right step we can take to advocate for our health." –––––––––––––––––– CONNECT WITH DR. JENN SIMMONS Website: www.realhealthmd.comInstagram: @drjennsimmons YouTube: @dr.jennsimmons Book: The Smart Woman's Guide to Breast Cancer –––––––––––––––––– CONNECT WITH DR. ANNA CABECA Website: www.dranna.comInstagram: www.instagram.com/thegirlfrienddoctor YouTube: www.youtube.com/@thegirlfrienddoctor TikTok: www.tiktok.com/@drannacabeca Facebook: www.facebook.com/thegirlfrienddoctor –––––––––––––––––– If this episode spoke to you, share it with a girlfriend, your daughters, your mother — every woman deserves this conversation. You are seen. You are informed. You are empowered.

Are mammograms truly protecting women — or is it time to rethink how we approach breast health? In this powerful and deeply nuanced conversation, Dr. Anna Cabeca sits down with former fellowship-trained breast surgeon turned integrative oncologist Dr. Jenn Simmons to unpack one of the most important questions in women's health today: Are mammograms safe — and are they enough? Together, they explore how conventional breast cancer screening became the standard, what the research actually says about radiation exposure and screening frequency, and why early detection is not the same as prevention. Dr. Simmons shares her personal turning point — from 17 years at the forefront of breast oncology to leaving conventional medicine and founding Real Health MD after her own health crisis. What she discovered changed everything: inflammation, toxicity, hormone disruption, and metabolic dysfunction matter far more than women are being told. This episode goes beyond mammograms. It dives into: • Radiation risks and over-screening • Alternative imaging options including thermography, ultrasound, and emerging technologies • Hormones and breast cancer — clearing the misinformation • Why anti-estrogen messaging can be harmful and incomplete • Bioidentical progesterone and protective mechanisms • Birth control pills and breast development risk • The power of metabolic health, fasting windows, detoxification, and terrain theory Most importantly, this conversation restores agency. You are not powerless when it comes to breast health. Knowledge is evolving. Screening is evolving. Hormone science is evolving. And you deserve the full picture. –––––––––––––––––– KEY TIMESTAMPS 00:00 Reimagining breast health and questioning the narrative 01:23 Introducing Dr. Jenn Simmons and her paradigm shift 09:47 From breast surgeon to integrative oncologist: her turning point 12:28 Functional medicine approach: "What caused the cancer?" 27:19 Mammography myths and reviewing the research 33:01 Radiation exposure: known carcinogen discussion 35:31 Biopsy concerns and imaging alternatives 42:07 Medical board pressures and guideline rigidity 53:04 "Anti-estrogen talk is misogynistic" 01:04:10 Birth control pills, teens, and breast cancer risk –––––––––––––––––– MEMORABLE QUOTES Dr. Jenn Simmons: "Radiation is a known carcinogen." "Any anti-estrogen talk is misogynistic." Dr. Anna Cabeca: "What caused your cancer to begin with?" "It takes more than hormones to fix our hormones." "There's always one next right step we can take to advocate for our health." –––––––––––––––––– CONNECT WITH DR. JENN SIMMONS Website: www.realhealthmd.comInstagram: @drjennsimmons YouTube: @dr.jennsimmons Book: The Smart Woman's Guide to Breast Cancer –––––––––––––––––– CONNECT WITH DR. ANNA CABECA Website: www.dranna.comInstagram: www.instagram.com/thegirlfrienddoctor YouTube: www.youtube.com/@thegirlfrienddoctor TikTok: www.tiktok.com/@drannacabeca Facebook: www.facebook.com/thegirlfrienddoctor –––––––––––––––––– If this episode spoke to you, share it with a girlfriend, your daughters, your mother — every woman deserves this conversation. You are seen. You are informed. You are empowered.

What does a pap smear test for, and what happens after an abnormal pap smear? In this episode of SHE MD, Mary Alice Haney interviews Dr. Thaïs Aliabadi to break down exactly what a pap smear is, how HPV affects cervical cancer risk, and what women need to know about abnormal results. A pap smear is a cervical cancer screening test that checks for precancerous and cancerous cells on the cervix. A pap smear does not test for ovarian cancer, uterine conditions, or all sexually transmitted infections. HPV testing is often performed at the same time because high risk HPV is the leading cause of cervical cancer.Can you have HPV with a normal Pap smear? What actually happens after an abnormal result? Dr. A answers these questions and more, explaining that while most HPV infections clear on their own within one to two years, monitoring and follow-up are key. The bottom line: cervical cancer is highly preventable with routine Pap and HPV screening—but annual well-woman visits are still essential for protecting your long-term health.Subscribe to SHE MD Podcast for expert tips on PCOS, Endometriosis, fertility, and hormonal balance. Share with friends and visit SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.Sponsors:Premier Protein: Find your favorite flavor at PremierProtein.com or at Amazon, Walmart, and other major retailers.Midi Health - Ready to feel your best and write your second act script? Visit JoinMidi.com today to book your personalized, insurance-covered virtual visit. Bobbie: If you want to feed with confidence too, head to hibobbie.com — to the formula trusted by parents and loved by their babies — 700k and counting.Peloton - Let yourself run, lift, sculpt, push, and go. Explore the new Peloton Cross Training Tread+ at onepeloton.com What You'll Learn:What a pap smear actually tests for and what it does not screenHow HPV and pap smear testing work together to prevent cervical cancerWhat abnormal pap smear results like ASCUS, CIN1, CIN2, and CIN3 meanWhen a normal pap smear still requires follow up or colposcopyWhy regular pap smear screening makes cervical cancer almost entirely preventableKey Timestamps:00:00 Introduction02:00 What a pap smear tests for and what it does not check03:40 HPV explained: low risk vs high risk and why it's common05:15 Screening guidelines and why pap smear alone is not enough07:15 What types of results you can get back from a pap smear 17:20 When you need a colposcopy and what happens during the procedure22:15 Biopsy results and CIN staging explained34:00 Treatment options: cryotherapy, LEEP procedure, and cold knife cone35:40 Risks of aggressive LEEP and pregnancy considerations38:00 HPV dormancy and common misconceptions41:45 HPV vaccine recommendations and prevention43:00 Final takeaway: pap smear schedule vs well woman examKey Takeaways:A pap smear screens for cervical cancer and HPV, not STDs, ovarian cancer, or uterine conditionsHigh risk HPV, especially types 16 and 18, may require colposcopy even with a normal pap smearColposcopy and cervical biopsy confirm whether precancer cells are present and guide treatmentMost HPV infections clear naturally within one to two yearsCervical cancer is preventable with routine pap smear and HPV screening, but annual well woman exams remain essentialResources Mentioned in This Episode:

PSA spikes, abnormal MRI results, and high PI-RADS scores often trigger immediate fear and for many men, that fear leads straight to biopsy. In this episode, Dr. Stephen Petteruti breaks down what PSA actually measures, how MRI technology fits into modern prostate cancer management, and why a high PI-RADS score does not automatically equal aggressive disease. Dr. Stephen discusses active surveillance, non-biopsy monitoring strategies, cardiovascular risk, hormone balance, and why overtreatment may compromise quality of life more than the cancer itself.  For men who value proactive healthcare, evidence-based medicine, testosterone preservation, and long-term vitality, this conversation offers clarity in a space dominated by urgency and assumption. It reframes prostate cancer care around informed consent, individualized risk assessment, and protecting both lifespan and healthspan.Before agreeing to your next scan or biopsy, press pause. Listen carefully. Ask better questions. Watch the episode of Stop the Prostate Biopsy Frenzy: The Truth About MRI, PI-RADS, and PSA.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

The Cincinnati-based company pioneered a vacuum-assisted breast biopsy system that is primarily used to diagnose breast cancer by obtaining large tissue samples, but is also used to treat and remove benign breast lesions.

Episode 78 - Tech Agnostic Tactics - Positioning and Biopsy Timing by AABIP

What's the secret to stress-free biopsy submission? Dr. Jodie Gerdin, Director of Anatomic Pathology at Antech, shares best practices for handling, packaging, labeling, and shipping biopsy samples to ensure diagnostic accuracy and timely results. Join us as Dr. Gerdin talks about her journey from emergency vet to pathology expert and reveals common mistakes that can jeopardize biopsy submissions — and how to avoid them. Learn how to protect precious tissue samples during transit, and the power of building a strong relationship with your pathology team. Tune in to elevate your biopsy game, improve patient outcomes, and build stronger partnerships with your diagnostic partners. Tails from the Lab is a production of Antech Diagnostics™. The intent of this podcast is to provide education and guidance with the understanding that any diagnostic testing and treatment decisions are ultimately at the discretion of the attending veterinarian within the established veterinarian-patient-client relationship. Our guest today is Jodie Gerdin, who is employed by Antech. We're sharing this so you have full transparency about the relationships involved.

I finally got the results of my breast biopsy and I talk about it in this episode. I waited almost 2 weeks, and at times it was very difficult. At some point before getting the results, I experienced a deep sense of acceptance,  in terms of how I would cope with the results. At the moment when my stress dissipated, I felt a full acceptance of this entire breast cancer experience and I realized I can get through whatever it is that's going to be happening, just like I did when first diagnosed, 2 1/2 years ago. I also talk about the importance of me doing the work now to make a decision about a mastectomy on the right, because what I really want do is prevent a future invasive cancer and I know that I'm high risk for that happening again. The content of this podcast is not intended to substitute professional medical advice, diagnosis, or treatment. Always consult a healthcare professional regarding your healthcare questions and concerns. This podcast contains opinions of the host. If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list!   LET'S CONNECT: connect@breastcancerlife.org  Follow us on Pinterest 

In today's VETgirl online veterinary continuing education podcast, we explore how multiple-site gastrointestinal biopsies compare to traditional jejunal biopsies in the ability to differentiate between lymphoplasmacytic enteritis (LPE) and low-grade intestinal T-cell lymphoma (LGITL) in cats.

In today's VETgirl online veterinary continuing education podcast, we explore how multiple-site gastrointestinal biopsies compare to traditional jejunal biopsies in the ability to differentiate between lymphoplasmacytic enteritis (LPE) and low-grade intestinal T-cell lymphoma (LGITL) in cats.

Picture this: a patient with early-stage breast cancer is sitting in front of you in the clinic. You are about to offer your expert management plan. The age-old question arises—should you really perform a sentinel lymph node biopsy, or could omission actually help this patient more? Today, we're tackling one of the hottest debates in modern breast cancer care.Should we rethink sentinel lymph node biopsy for select patients, and can skipping it actually improve quality of life without sacrificing cancer control? The stakes couldn't be higher—balancing accurate cancer staging and minimizing harm is the name of the game. Together, we're breaking down the latest evidence from the SOUND and INSEMA trials. What do these landmark studies mean for your patients, your practice, and the future of axillary management? Ready for a journal review that might just change your next consult? Hosts:- Rashmi Kumar, MD, PhDResident, University of Michigan General Surgery Residency ProgramTwitter/X: @RashmiJKumar- Melissa Pilewskie, MDAttending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine Twitter/X: @MPilewskie- Stephanie Downs-Canner, MDAttending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program Twitter/X: @SDownsCannerLearning Objectives:- Understand when and for whom it is safe and beneficial to omit sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients.- Identify the risks associated with foregoing SLNB, including loss of nodal staging, and analyze how this impacts treatment selection and prognosis.- Review key findings from the SOUND and INSEMA trials and their influence on axillary management.- Discuss implications for adjuvant therapy, genomic profiling, and multidisciplinary clinical practice.- Recognize which patient populations should still receive SLNB, and the importance of individualized, multidisciplinary decision-making.References:- Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1557–1564. doi:10.1001/jamaoncol.2023.3759 https://pubmed.ncbi.nlm.nih.gov/37733364/- Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer – primary results of the INSEMA trial. N Eng J Med. 2024. doi:10.1056/NEJMoa2412063.https://pubmed.ncbi.nlm.nih.gov/39665649/- Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794. PMID: 31566680; PMCID: PMC6777230. https://pubmed.ncbi.nlm.nih.gov/31566680/- Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570. https://pubmed.ncbi.nlm.nih.gov/37275963/Sponsor Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode of SurgOnc Today, we discuss the recently updated ASCO guidelines for axillary staging with sentinel lymph node biopsy in breast cancer, as well as considerations for their application in a multidisciplinary setting. This episode is moderated by Dr. Ashley Woodfin from the University of Wisconsin, who is joined by Dr. Clara Park from Brigham and Women's Hospital and Dr. Andrea Abbott from Medical University of South Carolina for a in-depth discussion regarding the guidelines implementation and important considerations.

What if the real war isn't political, cultural, or ideological—but biological, digital, and invisible?In this expansive and mind-bending conversation, Chris Crutchfield joins Word Up to expose the hidden architecture shaping modern reality—from global technology standards and biodigital convergence to the quiet integration of the human body into cyber-physical systems.Chris unveils his “Biopsy of a Psyop” map, connecting technology, media, food, pharmaceuticals, education, religion, history, and politics into a single coordinated system. We explore how standards—not politicians—drive global outcomes, why the Internet of Bodies changes everything, and how ancient law, redacted history, and spiritual suppression underpin modern control structures. We also dive into resets, lost civilizations, architecture that defies the official timeline, the weaponization of religion, and the question few are willing to ask: Are the entities steering the sham show even human?Watch on Odysee. Listen on Progressive Radio Network and podcast platforms everywhere.Part 2:danikatz.locals.comwww.patreon.com/danikatzAll things Dani, including books, courses, coaching + consulting, and her one-of-a-kind, critically acclaimed POP PROPAGANDA DIGITAL MEDIA LITERACY COURSE:www.danikatz.comPlus, schwag:danikatz.threadless.comFind Chris:https://www.instagram.com/67podcast/https://www.youtube.com/channel/UChCSEltGvbJZolsSfNiPUWAhttps://rumble.com/user/67podcastBiopsy of a Psyop map:https://drive.google.com/file/d/1TWLUptz2-x9RVC8wQmJA7RpRwQhHwA8m/viewShow notes:· Chris Crutchfield breaks down biodigital convergence and why the human body is becoming the next network node· The hidden role of global standards bodies in shaping technology, medicine, and governance· How 5G, IoB (Internet of Bodies), and cyber-physical systems intersect beneath mainstream narratives· Chris reveals his “Biopsy of a Psyop” map—connecting tech, media, food, pharma, politics, education, and history· Why politics is a distraction from the real battlefield: standards, protocols, and infrastructure· The redaction of history, lost civilizations, resets, and the architecture that “shouldn't exist”· The legal fiction of personhood, estates· Vatican City, City of London, Washington DC—and what sovereignty really means· The suppression of the sixth sense, biofields, and human electromagnetic awareness· Jesus, resets, orthodoxy, and how spiritual truth gets weaponized by institution

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn't an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Topics include the prioritization of treatment versus tissue acquisition, the nuances of bronchoscopic versus percutaneous biopsies, and the latest advancements in robotic and cryo-biopsy techniques. The experts also share their approaches to managing pneumothorax, the value of multidisciplinary collaboration, and case studies that highlight personalized patient care. Listeners gain valuable insights into the evolving landscape of thoracic oncology procedures and the importance of patient-centered decision-making. --- TIMESTAMPS 00:00 - Introduction04:12 - Cryobiopy vs. Non-Cryobiopsy08:43 - Biopsy and Ablation: Strategies and Considerations15:31 - Post-Therapy Imaging and Follow-Up25:18 - Treatment Options and Patient Decisions27:08 - Evaluating Ablation Techniques28:59 - Managing Lung Cancer Recurrence39:41 - Case Study: Young Male with Ground Glass Nodule43:15 - Concluding Thoughts

December 26, 2025 In this episode, Scott, Mark, and Ray Painter answer listener questions about the new 2026 prostate biopsy CPT codes. They clarify global periods, explain the differences between transrectal and transperineal approaches, and tackle the nuances of coding for MRI-guided procedures—especially when using systems like Promaxo. They also break down the use of 55715 for additional targeted lesions, when modifiers like 52 may apply, and how payers might interpret these new codes differently. The team emphasizes caution, payer communication, and the evolving nature of both coding and coverage guidance.Urology Advanced Coding and Reimbursement SeminarInformation and RegistrationPRS Coding and Reimbursement HubAccess the HubFree Kidney Stone Coding CalculatorDownload NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and AdminsPRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a Quote Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptp

Title: Employing Multi-Tissue Controls to Enhance Kidney Biopsy Protocol Education in a Program in Histotechnology Student Lab  Authors: Hyder Aljanabi, Damon Bendolph, Gabriella Casas, Yosan Embrafrash, Sara Hassan, Anastasja Kraft, Stephan Lloyd-Brown , Nida Mubeen, Minh Nguyen, Xena Orosco, Nicole Rivera, Moriam Sissoho, Tan Tang , Kaleena Ramirez, Toysha Mayer, Mark Bailey Abstract: In a Program in Histotechnology student laboratory, establishing a representative and clinical teaching laboratory environment is essential for preparing students to manage the complexities of diagnostic tissue processing. The objective of the project was to simulate real-world clinical procedures by integrating multi-tissue controls into student education competencies for kidney biopsy staining protocols. Students participated in the investigation, each receiving four pieces of formalin-fixed, paraffin-embedded (FFPE) tissue: kidney, liver, gastrointestinal tract (GI), and tonsil. The tissues served as controls to validate staining techniques commonly used in renal pathology. Students prepared tissue sections using a rotary microtome, sectioning tissue at four microns. In total, forty slides were prepared, with eighteen slides manually stained using specific histochemical methods. Stains included hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAMS), and the Gomori Trichrome technique. The results yielded identifiable cellular and structural features critical for diagnostic interpretation. A slide review was conducted, and acceptable representative slides were selected for digital imaging. In addition, the results demonstrated the four tissue types which may be approved to use as controls, due to the consistency of demonstrating staining characteristics and features required for evaluating kidney biopsy protocols. Upon technical validation, the use of multi-tissue controls contributed to educational and operational outcomes. Students gained quality assurance experience, and the experience reinforced special stain and laboratory operations competencies, teaching students how to conserve reagent use, and to reduce time and expense. Furthermore, the protocol introduced the application of digital pathology and quality assurance in a real-world lab setting. Our investigation supports the integration of multi-tissue controls in histotechnology education as a valuable tool for enhancing both learning and laboratory efficiency. Future studies are recommended to include additional tissue types, stains, and immunohistochemical markers, to further advance and expand histotechnology educational competencies.

Most men hear “you need a biopsy” and assume it's the responsible next step. But what if the real risk is the procedure itself?In this episode, Dr. Stephen Petteruti breaks down the painful, under‑recognized consequences of prostate biopsies: lingering pain, infections, hospitalizations, urinary obstruction, erectile issues, and long-term trauma to a vital gland. He highlights research suggesting that disrupting the prostate capsule may allow cancer cells to spread, a risk rarely mentioned in the exam room.Drawing from the ProtecT trial and other pivotal studies, Dr. Stephen makes a compelling case that biopsies do not improve survival and instead create a “treadmill” of anxiety, repeated testing, and unnecessary treatment. He shows how PSA, MRI, and clinical judgment can guide care safely without puncturing the gland.Learn how to protect your health without sacrificing your well‑being. Tune in to the episode of Prostate Biopsies: The Hidden Risk No One Told You About.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Advances in molecular diagnostics are reshaping how cancer is detected, monitored, and treated, and liquid biopsy is becoming central to that progress. This simple blood draw can reveal key tumor biology at diagnosis and over time, providing timely insight and guiding more precise decisions throughout a patient's journey. Clinicians now face an important challenge: knowing what is actionable today and what is coming next so more patients can benefit from the promise of these advances.As we kick off Season 7, host and patient advocate Karan Cushman expands this season's focus on Bringing Precision Medicine to Everyone with a deeper look inside the science of liquid biopsy. The conversation features two leaders shaping the field: Dr. Christian Rolfo, Division Director of Medical Oncology at The James Comprehensive Cancer Center at Ohio State University, and Dr. Roberto Borea, Medical Oncologist and emerging investigator from the Rolfo Lab.Together, they break down the scientific momentum driving liquid biopsy forward, including tumor fraction, MRD-guided treatment strategies, resistance monitoring, fragmentomics, and the expanding frontier of early detection. They also discuss the barriers that continue to slow broader adoption, such as assay variability, limited standardization, reimbursement gaps, and operational challenges in community settings.In this episode, we cover:• How tumor fraction is emerging as a meaningful real-time biomarker• Where MRD-driven escalation and de-escalation strategies are heading• The current promise and limitations of early detection and MCED testing• What is required to standardize liquid biopsy across reporting, workflows, and clinical trialsEpisode 70 offers a clear look at the advances researchers are helping drive right now and what these developments could mean for clinicians, laboratories, and patients in the near future.This conversation builds on episode 69 with Dr. Kashyap Patel, who introduced the foundations of liquid biopsy and its role in accelerating treatment decisions. Combined, these two episodes offer clinicians and patients an overview of where the science and real-world applications stand now and where the field is headed next.

Send us a textWelcome to the November Q&A! Today, we start with a topic that always stirs strong feelings—birth partners. From the gestures that truly helped to the ones that fell short, we chat about your experiences of your partner's support, presence, connection or not.Next, we respond to an emotional call for help from a sleep-deprived and emotionally exhausted mother whose husband threatens to call the cops on her for how she handled an overwhelming moment with her toddler. Today's episode includes a special guest appearance from Nancy Wainer, world-renowned midwife and the woman who coined the term VBAC. Nancy answers a listener's question about an anterior placenta in a planned VBAC and explains what her decades of experience tell us about how placentas behave in utero. We also discuss endometrial polyps and whether a biopsy could affect future fertility, how to handle conversations about home birth within a hospital work environment, and how to choose a midwife when you have numerous options and like them all. In Quickies, we cover making baby-wearing more comfortable, the myth that labor “starts” at one centimeter, chiropractic versus pelvic floor PT in pregnancy, relieving newborn gas, timing big changes during teething, postpartum nutrition, and even whether to skip airport scanners while pregnant. We end with each of us pondering which baby names we'd choose today and our favorite ways to spend a slow morning at home.VBAC: How to Plan for Success#257 | Labor & Delivery Nurses' Roundtable: How Their Hands are Tied to Doctors' Orders#273 | Special Q&A Featuring Nancy Wainer on VBAC and More********** Needed

 Get Fitness Lab, the #1 coaching app for people over 40 that adapts to YOUR recovery, YOUR schedule, and YOUR body. Build muscle, lose fat, and get stronger with daily personalized guidance. https://witsandweights.com/app--Are you over 40 and trying to stay muscular, lean, and strong, but PSA tests and prostate fears leave you confused? Worried that one elevated PSA could derail your strength training with an unnecessary biopsy?In this conversation with men's health expert Dr. Stephen Petteruti, we break down the truth about PSA testing, hormone health, and what most fitness podcasts get wrong about men's health and longevity. We talk about why body recomp and lifting weights matter even more as you age, how certain treatments impact testosterone and weight loss, and what proactive steps keep you training hard for decades.I share how evidence-based fitness shapes my own approach, and Steve gives a grounded perspective on protecting your hormones without sacrificing your physique.Today, you'll learn all about:0:00 – PSA tests and misunderstood prostate risks4:15 – Why biopsy thresholds are flawed9:42 – How lifestyle shapes cancer and longevity14:55 – Understanding atypical dormant cells18:40 – Repurposed drugs and monitoring protocol24:10 – Testosterone, muscle, and men's health31:42 – High-to-low dosing theory explained41:20 – Philosophy of vitality over fear48:05 – Strength training and premeditated nutrition50:37 – Where to find Dr. Petteruti's workEpisode resources:Intellectual Medicine Podcast. Start with this episode – Think Twice Before Getting a BiopsyWebsite: drstephenpetteruti.com Waitlist for his book “Fighting Cancer Like a Man”Instagram: @dr.stephenpetterutiYouTube: @intellectualmedicine Support the show

From post-menopausal spotting to at-home bowel tests. HPV to painful boobs. Ask us anything about cancer, we’ve got you covered! In this episode, Claire Murphy and Dr Mariam tackle your most pressing questions about some of the most common cancers affecting women, including cervical, ovarian, uterine, breast and bowel. They talk to the experts to answer all your questions including what it means if you test positive for HPV and whether you still need a cervical screen if you’re in a same-sex relationship or have already had the vaccine. Plus, they dive into your breast cancer concerns, addressing whether to get the BRCA gene test, if the age your mum was diagnosed with breast cancer matters and what to do about your random breast pain. They also demystify those intimidating doctor's visits (no, your doctor won't remember your butt), the accuracy of the at-home bowel tests and finding the appropriate support. THE END BITS All your health information is in the Well Hub. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20.Dr Mariam recommends The Bottom Line Podcast and the film A Little Bit of Heaven. For more specific information on the topics we discussed today, organisations like: Australian Gynaecological Cancer Foundation Ovarian Cancer Australia Australian Cervical Cancer Foundation National Breast Cancer Foundation Breast Cancer Network Australia iPrevent McGrath Foundation Bowel Cancer Australia Cancer Council And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Clare Scott, Dr Belinda Yeo, Dr. Penelope De Lacavalerie Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional. +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

It's the beginning of November 2025 and my opportunity to discuss news and information that has come out in the past month with Ellen Bayens of theceliacscene.com. Ellen keeps us up to date on what's happening regarding celiac disease and gluten free. First, let me urge you to sign the petition Celiac Canada is putting forth to the federal government regarding the cost of gluten free food and how they can assist the celiac population. This is a re-issue of the petition from last year, as unfortunately it died when an election was called. Last time we received more than 26,000 signatures. Let's try for 30,000 this time. Please click the link and send it on to anyone else who you think is interested on our behalf. You can find out more and sign the petition at – https://www.celiac.ca/petition-high-cost-of-gluten-free-food/ Ellen and I spoke at length about some of the information that came from the recent International Celiac Conference in Finland. Melissa Secord from the CCA was part of a Canadian "team" attending who did a great job presenting and interacting with experts from all over the world. We touched on research regarding a promising advancement in testing for celiac disease by a simple blood test. We also speak about research to try and "turn-off" the celiac switch and learn more about that. We learn why some people who think they might be celiac, might instead need to be on a temporary FODMAP diet to reset their digestive system with the help of a dietician. Here are the links to theceliacscene.com that Ellen and I spoke about – Celiac Canada Report | 2025 International Celiac Disease Symposium in Finland New Blood Test for Celiac Disease Could Dispense with Biopsies & the Gluten Challenge Gastroenterologist Develops World-First Diagnostic bBlood Test for Celiac Disease California to Require Food Allergen Labels on Menus by 2026 Think You Are Gluten Intolerant? Study Suggests You're Likely Wrong ... Celiac Teens Pay a Price for Sticking to the Diet Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Email – acdnceliacpodcast@gmail.com Celiac Kid Stuff – https://www.celiackidstuff.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL Email – sue@suesglutenfreebaking.com

Summary In this conversation, Doug Bennett shares profound insights on resilience and goal setting, stemming from a life-altering experience. He emphasizes the importance of recognizing life's fragility and the need to adjust priorities in the face of adversity. Doug advocates for viewing setbacks as opportunities for growth and stresses that while we cannot control external events, we can control our responses to them. This mindset is crucial for effective goal setting and personal transformation. Takeaways You're one lucky motherfucker, Doug. Setbacks, not dead ends. They're just speed bumps. You can't always control what happens, but you can choose how to respond. Your response to the event is what matters. Maybe there's a reason I'm here on this planet. You slow down, you take stock, adjust and keep moving. Broken bones, pride dented beyond repair teach us lessons. How quickly your priorities line up in order after a setback. That crash taught me something I now tell clients all the time. Goal setting is about preparing your mindset for change. Sound Bites "you're one lucky motherfucker, Doug." "Broken bones, pride dented beyond repair." "your response to the event." Chapters 00:00 Introduction to Goals and Life Lessons 00:55 Life-Altering Moments and Setbacks VALUABLE RESOURCES Website: http://dougbennett.co.uk Email: doug@dougbennett.co.uk LinkedIn: https://www.linkedin.com/in/financialdoug Download Your "Ten-Step Guide To Financial Freedom" Here: https://bit.ly/Struggle-Success BOOKS: Goals Do Come True is available to buy on Amazon: https://amzn.to/3phcy6Z Think Simple, Win Big is available to buy on Amazon: https://www.amazon.co.uk/Think-Simple-Win-Big-Business Enjoy, and come back for the latest podcast each Wednesday. Thank you for listening.

Here is more of him than you ever bargained for. I summarized some of his brilliant lectures about anti-aging medicine, including his innovative Parkinson's treatment.Support the show

Samina Farid built her career in oil and gas, founded her own company, and forged ahead in spaces where women are rarely seen. Through it all, she faced cancer twice and found strength that reshaped both her health and her work. Breaking barriers as the only woman in the room Building success in a male-dominated industry Facing cancer two times and turning challenges into purpose Key Questions Answered 1. How did Samina Farid cope with the challenges of being the only woman in a male-dominated field? 2. How did Samina come to start her own company, and what inspired its mission? 3. What was unique about Merrick Systems, and how did it contribute to the industry? 4. Why did Samina decide to sell her company, and what was that process like? 5.What steps did Samina take after her cancer diagnosis? 6. What did Samina learn about her genetic risk for cancer? 7. How did journaling and self-care practices help Samina during her cancer journey? 8. What message does Samina want to share with other women about health and self-care? Timestamped Overview 00:00 Discovery of Remarkable Women 04:12 Pre-Internet Oil Data Challenges 08:20 Grateful for Mentorship Journey 11:27 "Turbulent Life Changes" 15:44 Cancer Journey and Support 21:23 "Facing Cancer's Uncertainty" 24:12 Genetic Mutation: Cancer Risk Alert 25:44 Pancreatic Tumor and Whipple Surgery 28:49 Prioritize Health: Just Do It Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Dr Hajra is a GP and aesthetic doctor who was diagnosed with breast cancer in 2025, aged 37. In this episode of the Breast Cancer Now podcast, Hajra talks to Laura about the shock of her recent diagnosis, the effects of the chemotherapy treatment she's undergoing, and the treatment plan coming up, including a double mastectomy. Hajra also shares the differences in experiencing cancer as a doctor, compared with as a patient, and the surprising ways it's affected her. She tells Laura about her BRCA gene mutation, and how that news affected her outlook on her breast cancer diagnosis. You can find Dr Hajra on Instagram @drhajrasdiary If you'd like to find out more about Breast Cancer Now's support services, visit the Breast Cancer Now website or phone our free helpline on 0808 800 6000 (UK only). You can subscribe to this podcast on Spotify, Apple Podcasts, or wherever you get your podcasts. Every episode is available to watch or listen to on the Breast Cancer Now website. You can also watch it on YouTube. Key Topics: 1:56 Hajra's work as a GP and aesthetic doctor 6:23 Practising breast awareness as a doctor 9:02 Biopsies and scans, as a doctor 16:18 Receiving biopsy results with friends and family 18:09 Hajra is diagnosed with triple negative breast cancer 19:19 The treatment plan for Hajra's breast cancer 20:26 Being treated as a patient rather than as a doctor 21:40 Hajra is the first in her family with breast cancer 22:14 The physical effects of chemotherapy 23:42 Genetic testing for breast cancer gene mutations 29:03 Coping with the impact of a gene mutation diagnosis 33:22 Breast cancer treatment and fertility 39:22 The effect of chemotherapy on physical apperarance 44:57 Hajra's plan for aesthetic treatments after chemotherapy 47:28 Thoughts on the upcoming double mastectomy 50:15 Mental health and breast cancer treatment 53:17 Working during treatment for breast cancer 54:53 The importance of sharing your story 56:43 What it means to Hajra to "live well"

Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Podcast for 5 Years: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://blog.feedspot.com/medical_billing_and_coding_podcasts/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sonal's 16th Season starts up and Episode 8 features a Newsworthy update on claims being held by Medicare.Sonal's Trusty Tip and compliance recommendations focus on percutaneous needle breast biopsies.Spark inspires us all to reflect on resilience based on the inspirational words of Marianne Williamson.Checkout the Workshop for Telehealth Playbook for 2025-2026 on: ⁠⁠⁠https://kwadvancedconsulting.com/training-education-2/on-demand-webinars/webinar-registration/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Paint The Medical Picture Podcast now on:Spotify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id153044217⁠7⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Music: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Paint The Medical Picture Podcast on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7A⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Sonal on LinkedIn:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/sonapate/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠And checkout the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://paintthemedicalpicturepodcast.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PaintTheMedicalPicturePodcast@gmail.com⁠⁠⁠⁠⁠⁠

Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Podcast for 5 Years: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://blog.feedspot.com/medical_billing_and_coding_podcasts/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sonal's 16th Season starts up and Episode 7 features a Newsworthy spotlight on October as Breast Cancer Awareness Month.Sonal's Trusty Tip and compliance recommendations focus on fine needle aspiration biopsies.Spark inspires us all to reflect on resilience based on the inspirational words of Elie Wiesel.Checkout the Workshop for Telehealth Playbook for 2025-2026 on: ⁠⁠https://kwadvancedconsulting.com/training-education-2/on-demand-webinars/webinar-registration/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Paint The Medical Picture Podcast now on:Spotify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id153044217⁠7⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Music: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Paint The Medical Picture Podcast on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7A⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Sonal on LinkedIn:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/sonapate/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠And checkout the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://paintthemedicalpicturepodcast.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PaintTheMedicalPicturePodcast@gmail.com⁠⁠⁠⁠⁠

When should a parotid mass raise red flags? In this episode of the BackTable ENT podcast, Dr. Mirabelle Sajisevi, head and neck surgeon at the University of Vermont Medical Center, joins hosts Dr. Gopi Shah and Dr. Ashley Agan to discuss her approach to diagnosing and managing parotid malignancies. ---SYNPOSISDr. Sajisevi shares insights from her practice, including the importance of thorough physical exams, the utility of ultrasound and biopsy, and the intricacies of surgical planning. They also cover post-operative care, the role of radiation and chemotherapy, surveillance strategies, and the potential of emerging treatments and technologies.---RESOURCESDr. Mirabelle Sajisevi https://www.uvmhealth.org/providers/mirabelle-sajisevi-md

Turn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you. It's the best way to support this podcast and the movement we're building together: https://thewayfwrd.com/join/ Chris Crutchfield joins Alec for a conversation on how media, technology, and human physiology intersect in today's “post-truth” world. They discuss the role of video compression in deception, why physiological responses to perceived events matter more than factual accuracy, and Chris's “biopsy of a psyop” framework for understanding coordinated influence campaigns. For more details, links, timestamps and resources mentioned in this episode, visit our website: https://thewayfwrd.com/podcast/ep-194-the-biofield-the-internet-of-psyops-with-chris-crutchfield/ Resources and Links Instagram - https://instagram.com/67podcast  YouTube - https://www.youtube.com/@sixsevenpodcast  “Biopsy of a Psyop, See”  Map – https://67podcast.short.gy/BiopsyMap  Campsite - https://campsite.bio/67podcast  Related Links & References What If My Body is Brilliant? — https://www.youtube.com/watch?v=Jhv2b5auS3c  Sabrina Wallace — https://odysee.com/@Psinergy:a  The End of Covid — https://music.amazon.com/es-us/podcasts/7b17bf72-7017-4f5a-812f-680eaf96174f/episodes/ba1b9073-a3fd-4998-8beb-5090dc01b3fd/the-collective-resistance-podcast-discussing-the-end-of-covid-w-alec-zeck    The Way Forward podcast is sponsored by: New Biology Clinic: Redefine Health from the Ground Up Experience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit https://NewBiologyClinic.com and use code TheWayForward for $50 off activation. Way Forward members get the fee waived: https://thewayfwrd.com/membership-sign-up/ ————————— RMDY Collective: Homeopathy Made Accessible High-quality remedies and training to support natural healing. Enroll: https://rmdyacademy.org/?bg_ref=MKho6KZowaExplore: https://rmdycollective.org/?bg_ref=MKho6KZowa —————————  

Aubrey Masango speaks to Dr Sithembile Ngidi, Clinical & Radiation Oncologist as they discuss the importance of breast cancer awareness, the latest developments in breast cancer research, treatment options, and innovative therapies.Tags: 702, Aubrey Masango show, Aubrey Masango, Breast Cancer Awareness, Dr Sithembile Ngidi, Mammogram, Chemotherapy, Malignant tumor, Biopsy, Breast lumps, Triple negative breast cancer The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In this groundbreaking episode, we dive deep into MOJO Health's "Data Iceberg" concept that's revolutionizing cancer care. Many people make life-changing medical decisions using only 2 types of data - biopsy results and imaging scans. If you go to the most advanced cancer centers, you likely use 6, but there are 7 additional categories of health data hiding beneath the surface that will transform your healing strategy.What You'll Discover:- Why most healthcare operates on "tip of the iceberg" data- The 13 hidden data categories that predict treatment success- How molecular DNA profiling creates personalized treatment roadmaps- The power of circulating tumor DNA (liquid biopsies) for real-time monitoringPerfect for: Cancer patients, survivors, caregivers, healthcare advocates, and anyone who wants to transform from reactive to proactive healthcare.Remember: Data G's don't just hope their treatment is working. They know.Resources Mentioned:For our downloadable Guide to Be a Data G, please go to mojohealth.org/datagguideTo set up an appointment with Oscar Sierra, please reach out to https://www.sierracollaborativemed.com/To see National Cancer Institute's page the blood biomarkers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-listAnd here for information on different types of data to request: https://www.mojohealth.org/be-a-data-g-1Other Podcasts to watch:#4 A Data G's Guide to Beating Cancer w/ Julie Stevens and Oscar Sierra, L.Ac.#6 BRCA2 Data Dilemma: Lessons in Gene Expression#8 How Genomic Testing Can Transform Your Cancer JourneyWhat tests do you need your doctor to order? Biopsy, Imaging, Circulating Tumor DNA, and Molecular DNA of the Tumor.Basically everything else you can order on your own through Direct Patient Labs: https://www.mojohealth.org/direct-labs-mojo-panelsConnect with Julie Stevens and the MOJO Movement: Instagram: https://instagram.com/mojohealthorg TikTok: https://tiktok.com/@julie.stevens97YouTube: https://www.youtube.com/@mojohealth Facebook: https://facebook.com/mojohealthorg Website: https://www.mojohealth.org/DISCLAIMER: The views, thoughts, and opinions expressed on this podcast are the speaker's own and do not represent the views, thoughts, and opinions of MOJO Health Cooperative LLC, a Georgia Limited Liability Company, its respective officers, directors, employees, agents, or representatives. This podcast is presented by MOJO Health Cooperative, and cannot be copied or rebroadcast without consent. The material and information presented here is for general information purposes only, and not intended to supplant the expert advice and/or consultation of a medical doctor and/or a licensed physician, and/or an attorney. In short, this podcast is not intended to replace professional medical advice, nor legal advice. The "MOJO Health" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Again, none of the content of this podcast should be considered legal advice, nor medical advice. As always, consult a lawyer and/or a licensed physician in lieu of relying upon the advice of any of the participants of this podcast. The host(s) of this podcast are not licensed lawyers, physicians, doctors of osteopath, nor medical doctors in any jurisdiction anywhere. The host(s) of this podcast do not practice medicine and do NOT profess to be able to do any of the following: (1) diagnose, heal, treat, prevent, prescribe for, or removing any physical, mental, or emotional ailment or supposed ailment of an individual; (2) engage in the end of human pregnancy; (3) treat human ailments; nor (4) perform acupuncture. MOJO Health Cooperative LLC is not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.

In this episode of TGen Talks, we sit down with three researchers who are working to make cancer care safer and more precise for some of the most vulnerable patients—children with rare brain tumors. Dr. Floris Barthel, Dr. Shea Gallus, and graduate student Sharvari Mankame are part of a team at TGen and Phoenix Children's Hospital exploring liquid biopsies—a method that uses small samples of blood or spinal fluid to detect and monitor brain cancer. This approach could reduce the need for invasive surgeries, which are especially hard on young patients. Our guests explain how liquid biopsies work, what they're learning from genetic markers called K-mers, and how artificial intelligence is helping them analyze tumor DNA in ways that weren't possible before. Their goal is to find a better way to track cancer in real time—giving doctors more information while easing the burden on patients and families. While this science is still developing, it's already showing real potential to shift how we approach diagnosis and treatment—not just in pediatrics, but across cancer care.

As always, you bring the best questions for these grab bag episodes. Today, we cover dog autoimmune diseases (though cats find their way to make it in a bit). How do you tell the difference between DLE and PF?What if an owner can't biopsy the case?How do you treat SLO? Sebaceous adenitis?Find the answers to these questions and more on this week's episode of The Derm Vet podcast!00:00 Intro01:30 SLO & sabaceous adenitis09:40 Steroids and Autoimmune diseases12:23 What to do when owners can't biopsy the case15:12 Pemphigus foliaceus in Dogs16:05 Pemphigus foliaceus in Cats17:07 Autoimmune Disease vs Allergies18:31 Differentiating between DLE and Pemphigus Exfoliation in dogs21:48 Outro

Prostate cancer deaths have been climbing over the last decade in part due to confusion over who should be screened and treated. In part 1 of a three-part series on prostate cancer, host Sandra Lindsay speaks with Samir Taneja, MD, a trailblazer in urologic cancer innovation, to explore how modern diagnostics and treatments, such as the groundbreaking use of MRI technology, are transforming patient outcomes. As Northwell's senior vice president and system chair of urology, Dr. Taneja provides invaluable insights into the shifting landscape of prostate cancer care and the critical importance of early detection. Tune in to understand the vital steps needed to increase awareness and save lives. About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit the health system's job portal and explore our many opportunities.    

Blind biopsies leave questions unanswered. In this episode of BackTable OBGYN, host Dr. Mark Hoffman welcomes back Dr. Linda Bradley, an expert in obstetrics, gynecology, and hysteroscopy from the Cleveland Clinic, to discuss the benefits and advancements of direct visualized endometrial sampling over traditional blind biopsy techniques. ---This podcast is supported by:Medtronichttps://www.medtronic.com/en-us/healthcare-professionals/specialties/gynecology/product-portfolio.html---SYNPOSISDr. Bradley emphasizes the importance of hysteroscopy for accurate diagnosis and treatment of various gynecological issues, including abnormal uterine bleeding. They explore the limitations of blind biopsies and the advantages of hysteroscopy in detecting focal lesions, avoiding unnecessary hysterectomies, and ensuring patient safety. The discussion also touches on the economic and procedural challenges in adopting hysteroscopy more widely in clinical practice.---TIMESTAMPS00:00 - Introduction 03:30 - The Evolution of Hysteroscopy at Cleveland Clinic04:49 - Challenges and Innovations in Hysteroscopy06:30 - Clinical Insights: Direct Visualized Endometrial Sampling12:03 - Case Studies and Practical Applications15:46 - The Importance of Visual Examination in Gynecology20:03 - Advocating for Hysteroscopy in Medical Practice31:07 - Patient History and Trauma Considerations31:34 - Cancer Detection and Missed Diagnoses32:14 - Challenges with Unscheduled Bleeding32:56 - Case Study: Blood Transfusions and Hysterectomy33:38 - Importance of Hysteroscopy34:43 - Hysteroscopy Techniques and Best Practices37:41 - Ultrasound and SIS (Saline Infusion Sonohysterography) for Imaging38:45 - Post-Operative Care and Follow-Up47:41 - Environmental and Economic Considerations in Healthcare52:51 - Final Thoughts and Patient Advocacy

Liquid biopsy is breaking speed and access barriers in precision oncology. In this episode of the Precision Medicine Podcast, part of our series Bringing Precision Medicine to Everyone and the first in a two-part focus, founder and host Karan Cushman speaks with Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates, author, and national leader in value-based oncology.Together, they explore how liquid biopsy is changing the diagnostic and treatment landscape. This blood-based test can deliver results in days, be repeated as needed, and reduce the need for invasive procedures. Tissue biopsy remains important, but when the samples are too small or unsuitable for testing, liquid biopsy provides a valuable alternative in guiding treatment decisions and monitoring disease.For patients with aggressive “turbo cancers” such as diffuse large B-cell lymphoma or small cell lung cancer, the time saved can be lifesaving. Karan shares her own experience with DLBCL, while Dr. Patel highlights real-world cases where liquid biopsy revealed actionable mutations, informed therapy, or enabled minimal residual disease (MRD) monitoring.Finally, Dr. Patel underscores the need for standardization and payer alignment to move liquid biopsy from innovation to everyday practice. This candid discussion frames liquid biopsy not as a futuristic idea, but as a clinically powerful and scalable tool that is closing gaps in precision oncology today.

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Faina Nakhlis the upgrade rate to ductal carcinoma in situ or invasive cancer following excision for patients diagnosed with flat epithelial atypia on core biopsy, as reported in the article, "Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).”

Host Dr. Amanda Redfern welcomes Dr. Claudia Prospero Ponce, a neuro-ophthalmologist and ocular pathologist, to share her unique perspective on how to diagnose giant cell arteritis (GCA) when temporal artery biopsies are not classically positive.  For more information about pathological markers in GCA, check out this paper referenced in the episode: Sultan H, Smith SV, Lee AG, Chévez-Barrios P. Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. Am J Ophthalmol. 2018;193:45-53. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Rethinking prostate care begins with one powerful question: are biopsies always necessary or is there a better way to protect both life and vitality?In this episode, Dr. Stephen Petteruti speaks directly to those who value longevity and proactive health. He walks through compelling data from studies like TOAD, CHAARTED, STAMPEDE, and PEACE-1, showing that aggressive prostate cancer treatments often offer little survival benefit.Dr. Stephen doesn't advocate ignoring abnormal PSA or MRI results. Instead, he encourages you to ask smarter questions about your care. He outlines practical steps for non-invasive monitoring and decision-making that prioritizes long-term health.If you or someone you care about is navigating prostate care, tune into the full episode of Metastatic Disease: Why Prostate Biopsies Can Do More Harm Than Good.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative to liver biopsy. A Japanese cohort study linked breakfast skipping and late dinners to higher fracture risk, with combined habits raising risk by nearly 25%. Finally, a global meta-analysis suggests shingles vaccination reduces major cardiovascular events by ~16–18%, though most evidence is observational.

Dr. Shravan Sridhar explores the evidence-based approach to transthoracic needle biopsy, covering indications, performance metrics, complications, and risk mitigation strategies. Listeners will gain practical insights on patient selection, technical considerations, and navigating controversial scenarios to optimize outcomes in clinical practice. Evidence-based Approach to Transthoracic Needle Biopsy: Procedural Techniques, Risks, and Controversies. Sridhar et al. RadioGraphics 2025; 45(9):e240094.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Justine Turner about a non-biopsy approach to diagnosis for celiac disease in children. Dr. Turner is a Professor of Pediatrics and Divisional Director for the Division of Gastroenterology and Nutrition at the University of Alberta and also the medical lead for the Multidisciplinary Pediatric Celiac Disease Clinic at Stollery Children's Hospital in Edmonton. Learning Objectives:Review current clinical guidelines for the diagnosis of celiac disease in childrenUnderstand the potential pros and cons of a non-biopsy approach to diagnosis for celiac diseaseRecognize the potential impacts of serologic diagnosis for celiac disease on patients, their families and healthcare systemsLinks (to be added!!):Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and NutritionNASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related DisordersEuropean Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020Positive Predictive Value of Tissue Transglutaminase IgA for Celiac DiseaseSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Synopsis: Some of the most game-changing ideas in healthcare come from unexpected intersections—where engineering meets biology, and where data meets patient urgency. This episode of Biotech 2050 dives into that exact convergence with a look at how one visionary leader helped pioneer blood-based cancer diagnostics. Co-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech's most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale. The conversation explores the technology behind liquid biopsies and companion diagnostics, the challenges of insurance reimbursement, and how Guardant's innovations are helping detect recurrence and screen for early-stage cancers—all through a simple blood test. Hosted by Biotech 2050 Co-Founder Rahul Chaturvedi, this episode is packed with insights on biotech leadership, pharma partnerships, and building a company that scales with both urgency and heart. Biography: AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.

World renowned, New York Times bestselling author, Joel Fuhrman, MD, has been sharing evidence-based research about healing our bodies with a Nutritarian lifestyle. There is such a powerful connection between a plant-based diet and cancer prevention. Dr. Fuhrman goes beyond nutrition to address an often-overlooked topic: the risks and realities of conventional cancer screenings. From […]

The FiltrateJoel Topf Bluesky: @kidneyboy.bsky.social‬AC @medpeedskidneys.bsky.social‬Nayan Arora @captainchloride.bsky.social‬Special Guest Vandana Niyyar Professor of Medicine at Emory School of MedicineEditing byNayan AroraThe Kidney Connection written and performed by by Tim YauShow NotesAmerican Society of Diagnostic and Interventional Nephrology (Website)ASDIN List of training sitesPlacement, performance and complications of the Ash Split Cath hemodialysis catheter (PubMed)Platelet Function Assay FAQ (PDF)Saint Clair's Vascular Access Center where we do outpatient biopsies (Website)The studies: NephJC Summary Prasad Study KI Reports Chakrabarti in Kidney 360Thromboelastogram (TEG) (Life in the Fastline)Elastigirl (Wikipedia)Association of Kidney Biopsy Needle Gauge with Post-Procedure Complications and Biopsy Adequacy (PubMed)Complications of Percutaneous Renal Biopsy (PubMed)Tubular SecretionsNayan Quarterback on Netflix (Wikipedia)AC The Rehearsal on HBO (Wikipedia)Joel The Detroit Tigers (MLB)

Prostate biopsy is evolving rapidly, offering urologists more precision - but also more decisions. In this episode of BackTable Urology, Dr. Ricardo Sánchez-Ortiz, a pioneer in robotic surgery and neuro-urology in Puerto Rico, joins host Dr. Jose Silva to discuss the shifting landscape of prostate biopsy and emerging strategies that improve accuracy and personalize care. --- SYNPOSIS The conversation explores the transition from transrectal to transperineal prostate biopsy, emphasizing the role of PSA density and modern imaging in refining patient selection. Dr. Sánchez-Ortiz highlights the value of biomarkers in improving diagnostic accuracy and focal therapy as a promising, less invasive treatment option.Beyond clinical innovations, the doctors also discuss the importance of communication in urology practice. Dr. Sánchez-Ortiz shares how tools like WellPrept can enhance patient education and engagement, reinforcing the need for individualized care strategies in an increasingly complex diagnostic landscape. --- TIMESTAMPS 00:00 - Introduction 02:14 - Evolution of Prostate Biopsy Methods17:51 - Transperineal vs. Transrectal Approaches22:52 - Use of Sedation35:10 - PSA Screening41:48 - Rise in Metastatic Prostate Cancer50:44 - Potential of Focal Ablation55:58 - Use of WellPrept --- RESOURCES WellPrept:https://www.wellprept.com/